Visit us at Booth 2710 to meet the MiraDx team and learn how genetic insights can provide actionable adverse event risk stratification before radiation therapy begins, helping inform more personalized treatment decisions.
Featured Scientific Presentation
Presented by Amar Kishan, MD, UCLA Radiation Oncology
Tuesday, September 29, 3:45 PM – 3:55 PM ET | Room 210
Germline Biomarker for Late Genitourinary Adverse Events after Radiotherapy for Prostate Cancer: Validation in Multiple Prospective Trials
Other Scientific Presentations
Presented by Joanne Weidhaas, MD, PhD, UCLA Radiation Oncology
Sunday, September 27, 5:17 PM – 5:32 PM ET | Room 156
Germline microRNA-Based Signatures to Predict Radiation Treatment Toxicity
Monday, September 28, 10:45 AM – 12:00 PM ET | Poster Hall – Exhibit Hall A
mRNA and miRNA Expression Differences Between High- and Low-Risk PROSTOX Patients
Tuesday, September 29, 5:40 PM – 5:45 PM ET | Room 205
Germline Biomarker Predicts Adverse Events Following SBRT to the Prostate Fossa After Radical Prostatectomy